

mb
D187 intramuscular, subcutaneous, intratechal, the buccal, inoculation into tissue, or by an implant.

102 (new). A diagnostic agent comprising a trimeric polypeptide complex according to claim 68.

12 103 (new). A diagnostic agent according to claim 102 wherein the at least one heterologous moiety is a detectable label.

104 (new). A method for diagnosis of a disease comprising contacting a sample with a diagnostic agent according to claim 102, and correlating the degree of interaction between the agent and the sample, with the status of the disease.

105 (new). In a method of displaying a protein library the improvement which comprises operably linking the library proteins to a living or nonliving support by means of a trimeric polypeptide complex according to claim 68.

REMARKS

Applicants have cancelled the unelected claims 2-18, 25, 28-59 and 62-67. Claim 1 has been retained because 19 is dependent on it.

New claim 68 is intended to ultimately replace claim 19 as the main claim to the elected oligomer peptide constructs. However, claim 19 is retained for the time being.

Claims 20, 21, 26, 27, 60 and 61 have been cancelled in view of new claims 68 et seq.

Claims 22-24 have been amended to depend from claim 68.

Basis for new claims 68-105 appears as follows.

Claim 1: Basis for the wording

"A trimeric polypeptide" can e.g. be found on page 1, lines 1-2, and in the abstract;

"complex" can e.g. be found on page 6, line 26 and page 7, lines 10-11;

"three monomer polypeptides" can e.g. be found on page 33, lines 19-20;

"each of said monomer polypeptides comprises a tetranectin trimerising structural element (TTSe)" can be found in previous claim 1;

"said TTSE being a polypeptide having at least 68% amino acid sequence identity with the consensus sequence shown in Fig. 2" can be found in previous claim 9 and on page 17, lines 5-11;

"at least one of said monomer polypeptides is covalently linked to at least one heterologous moiety" can be found in previous claim 1.

Claims 69-72: Basis for the sequence identity percentages can be found on page 17, lines 8-13.

Claim 73: Basis for the wording "the TTSE comprises the consensus sequence shown in Figure 2" can e.g. be found on page 21, lines 18-19.

Claim 74: Basis can be found in previous claim 8.

Claim 75: Basis for the wording "the TTSE is derived from human tetranectin and comprises the amino acid residues V17 to V49 (exon 2) shown in Figure 1" can be found on page 8, line 13 and in Figure 1.

Claim 76: Basis for the wording "the TTSE derived from human tetranectin further comprises the amino acid residues C50 to K52 (exon 3) shown in Figure 1" can be found on page 8, lines 18-20 and in SEQ ID NO:7, page 60.

Claim 77: Basis for the wording "the monomer polypeptides further comprises the amino acid residues E1 to D16 (exon 1) shown in Figure 1" can be found on page 8, lines 12-13.

Claim 78: Amino acid residue No. 6 has been deleted as it is not a part of exon 2 (cf. SEQ ID NO:7, page 60 and Fig. 1).

Claim 79: Basis can be found in previous claim 11.

Claim 80: Basis can be found in previous claim 12.

Claim 81: Basis can be found in previous claim 13 and on page 22, lines 5-15. The wording has been changed in order to improve the language and clarity.

Claim 82: Basis can be found in previous claim 20.

Claim 83: Basis can be found on page 16, lines 28-36 ("up to six copies of one particular polypeptide sequence or functional entities").

Claim 84: Basis can be found in previous claim 3.

Claim 85: Basis for the wording "said at least one heterologous moiety is positioned C-terminally to the monomer polypeptide" can be found on page 22, lines 29-33.

Claim 86: Basis for the wording "said at least one heterologous moiety is positioned N-terminally to the monomer polypeptide" can be found on page 22, lines 29-33.

Claim 87: Basis can be found in previous claim 21.

Claim 88: Basis can be found in previous claim 14.

Claim 89: Basis can be found in previous claim 15.

Claim 90: Basis can be found in previous claim 27.

Claim 91: Basis can be found in previous claims 28-30.

Claim 92: Basis can be found in previous claim 34 as originally

USSN - 09/445,576

filed.

Claim 93: Basis can be found in previous claim 35.

Claim 94: Basis can be found in previous claim 36.

Claim 95: Basis can be found in previous claim 37.

Claim 96: Basis can be found in previous claim 38.

Claim 97: Basis can be found in previous claim 39.

Claim 98: Basis can be found in previous claim ~~47~~⁴⁷.

Claim 99: Basis can be found in previous claim 47.

Claim 100: Basis can be found in previous claim 48.

Claim 101: Previous claim 52 renumbered.

Claims 102 and 103: Basis can be found in previous claim 66.

Claim 104: Previous claim 54 renumbered.

Claim 105: Previous claim 67 renumbered.

All claims (save 19) are now dependent on claim 68. Claims 19 and 68 are both directed to the invention of group II.

Certain new claims are directed to product comprising the oligomer of claim 68: claim 91 is to a kit, claims 98-99 to a composition, claims 102-103 to a diagnostic agent, and claim 94 to a chimeric product.

New claim 90 is to a method of making (cp. prior claim 27) and claims 92, 93, 95-97, 100-101 and 104-105, to various methods of use. Under PCT unity rules, these are properly joined with

USSN - 09/445,576

claim 68.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
F:\,P\Plou\Thogersen1\ptopreamend.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 22, 23 and 24 have been amended as follows:

22 (amended). An [oligomer] trimeric polypeptide complex according to claim [21] 68, wherein the at least one heterologous moiety which is positioned N-terminally to a TTSE and the at least one heterologous moiety which is positioned C-terminally to a TTSE are part of the same [monomeric polypeptide construct] monomer polypeptide.

23 (amended). An [oligomer] trimeric polypeptide complex according to claim [21] 68, wherein the at least one heterologous moiety which is positioned N-terminally to a TTSE and the at least one heterologous moiety which is positioned C-terminally to a TTSE are part of two separate [monomeric polypeptide constructs] monomer polypeptide.

24 (amended). An [oligomer] trimeric polypeptide complex according to claim [19] 68 wherein each monomer polypeptide construct is designed so as to disfavour formation of trimers including two monomer polypeptide constructs having identical TTSEs.

Claims 2-18, 20, 21 and 25-67 have been deleted.

Claims 68-105 have been added.